目的评价K-ras基因突变状态与西妥昔单抗/帕尼单抗治疗mCRC疗效间的关系。方法检索Pubmed、CENTRAL(the Cochrane Central Register of Controlledtrials)、EMBASE、中国期刊全文数据库(CNKI)、美国临床肿瘤学会(ASCO)、欧洲肿瘤协会(EMSO)官方网等,公开发表的K-ras基因突变状态与西妥昔单抗/帕尼单抗治疗mCRC疗效间关系的研究(包括前瞻性和回顾性)。应用Stata 11.0统计软件分析K-ras基因突变状态与西妥昔单抗/帕尼单抗治疗mCRC疗效间的关系。结果共12项研究1 622例受试者纳入分析,合并分析显示:mCRC患者中K-ras基因突变率为P=39%(95%CI:37%~44%);K-ras野生型和突变型患者西妥昔单抗/帕尼单抗治疗的客观有效率(CR+PR)分别为P=18%(95%CI:15%~26%)和P=9%(95%CI:2%~15%);与K-ras突变型相比,K-ras野生型患者西妥昔单抗/帕尼单抗治疗的客观有效率优势比OR(odds ratio)=5.10(95%CI:2.84~9.14)。结论 mCRC中约有40...
【英文摘要】
OBJECTIVE To evaluate relationship between the K-ras gene mutation status and response to cetuximab/ panitumumab for mCRC.METHODS By searching PubMed,CENTRAL,EMBSE,CNKI,ASCO and ESMO databases,the open published studies about the relationship between the K-ras gene mutation status and response to cetuximab/panitumumab for metastatic colorectal cancer were searched.The pooled ORR for metastatic colorectal cancer treated with cetuximab/panitumumab associated with the K-ras gene mutation status was calculated ...
| 
推荐 
点击下列相关研究机构和相关文献作者，可以直接查到这些机构和作者被《中国知识资源总库》收录的其它文献，使您全面了解该机构和该作者的研究动态和历史。
